Union leaders representing 50,000 nurses and other U.S. medical staff reached a tentative agreement with Kaiser Permanente on November 13, averting a strike that could have disrupted patient care at hospitals.
A study published in Nature Communications reveals that patients who had been hospitalized with severe Covid-19 might not be totally safe after recovery, as they are more likely to harbor self-attacking antibodies than those who did not have the virus.
Moderna’s Covid-19 Vaccine Shows Early Promise
Antibodies, Clinical Trials, Coronavirus Disease 2019 (COVID-19), COVID-19 Vaccines, Data, Immune Response, Kaiser Permanente, Messenger RNA (mRNA) Vaccines, National Institutes of Health, New England Journal of Medicine, Patient safety, R&D, Researchers, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)According to data published in The New England Journal of Medicine, a Phase I trial of Moderna’s mRNA vaccine against SARS-CoV-2 demonstrated promising safety and immune response in all patients involved in the study.